Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension and chronic kidney disease, has announced its participation in three upcoming investor conferences. The company will engage in fireside chats at the Guggenheim Healthcare Innovation Conference (November 12, 4:00pm EST), Stifel Healthcare Conference (November 19, 10:20am EST), and Evercore ISI HealthCONx Conference (December 4, 4:15pm EST). Live webcasts will be available on the company's website under the Investor Relations section, with replays accessible for approximately 90 days.

News Market Reaction

+10.66%

1 alert

+10.66% News Effect

On the day this news was published, MLYS gained 10.66%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.

Guggenheim Healthcare Innovation Conference:
Date:	Tuesday, November 12, 2024
Time:	4:00pm EST
Format:	Fireside Chat
Webcast Link
Stifel Healthcare Conference:
Date:	Tuesday, November 19, 2024
Time:	10:20am EST
Format:	Fireside Chat
Webcast Link
Evercore ISI HealthCONx Conference
Date:	Wednesday, December 4, 2024
Time:	4:15pm EST
Format:	Fireside Chat
Webcast Link

Live webcasts of the fireside chats can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

What investor conferences is Mineralys Therapeutics (MLYS) attending in late 2024?

Mineralys Therapeutics is participating in three conferences: Guggenheim Healthcare Innovation Conference on November 12, Stifel Healthcare Conference on November 19, and Evercore ISI HealthCONx Conference on December 4, 2024.

When is Mineralys Therapeutics (MLYS) presenting at the Guggenheim Healthcare Conference?

Mineralys Therapeutics is presenting at the Guggenheim Healthcare Innovation Conference on Tuesday, November 12, 2024, at 4:00pm EST in a fireside chat format.

How long will the webcasts of Mineralys Therapeutics (MLYS) investor conferences be available?

The webcasts will be available for replay on the company's website for approximately 90 days after the events.

What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?

Mineralys Therapeutics focuses on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone.